BioWorld MedTech

Oct. 21, 2011

Abbott reports plan to split into two separate companies

Two companies are better than one or so Abbott (Abbott Park, Illinois) has decided. The company plans to split into two publicly traded companies, one in diversified medical products and the other in research-based pharmaceuticals. Read More

Crimson's research memo details total cost of device documentation

International report: Cook's Spectrum Turbo-Ject PICC available in Canada

Washington roundup: FDA urged to tread lightly on artificial pancreas guidance

Agreements/contracts: Zimmer to distribute Benvenue's Kiva VCF

Deals roundup: Misonix sheds lab, forensic business for $1.5 million

Financings roundup: Sphere Medical looking to raise $24 million in an IPO

HIT roundup: Segasist wins first FDA 510(k) for Segasist P-AC

People in the News

Med-Tech Notes: RF Surgical works with UNC hospitals

Product Briefs

CareFusion initiates Class I recall of EnVe ventilators

MDD's Diagnostic Extra

Today's news in brief

BioWorld

BioWorld briefs for June 12, 2026.

Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis

BioWorld

Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...

Ethyreal launches to treat the underlying cause of Graves’, TED

BioWorld

Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...

Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?

BioWorld

Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...

Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists

BioWorld Science

Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.